Intravenous (IV) Ibuprofen Market Size & Share 2025 – 2034

Intravenous Ibuprofen Market Size

The global intravenous ibuprofen market size was valued at around USD 7.6 billion in 2024 and is estimated to grow at 8.6% CAGR from 2025 to 2034. The global market is experiencing significant growth, primarily driven by the increasing prevalence of conditions such as arthritis, cardiovascular diseases, and various cancers.

Many forms of cancer, including osteosarcoma (bone cancer), nerve cancer, and leukemia, can result in mild to severe pain. For example, the American Cancer Society (ACS) reports that approximately 1,000 new cases of osteosarcoma are diagnosed annually in the U.S. The high bioavailability and rapid analgesic action of IV ibuprofen are contributing to its growing adoption in medical settings for effective pain management.
 

The rising prevalence of musculoskeletal diseases is a major factor driving the market growth for intravenous (IV) ibuprofen. According to the World Health Organization (WHO), around 1.71 billion people worldwide were affected by musculoskeletal conditions in 2022, underscoring the substantial need for effective pain management drugs. Additionally, the expansion of orthopedic hospitals and diagnostic centers has enhanced the ability to diagnose and treat these conditions. For instance, as reported by Becker's Healthcare, there were 27,639 orthopedic surgeons practicing in the U.S. as of 2023, indicating a growing demand for effective pain relief options, including IV ibuprofen.
 

Intravenous (IV) ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) administered directly into the bloodstream through an intravenous line to treat pain and inflammation. Healthcare providers commonly use IV ibuprofen in post-operative care, emergency rooms, and for patients who are unable to take oral medications due to conditions like nausea or vomiting.
 

Intravenous Ibuprofen Market Trends

• The healthcare sector's efforts to combat the opioid crisis have led to a greater adoption of non-opioid analgesics, especially IV ibuprofen, in clinical settings for pain management. For example, the Centers for Disease Control and Prevention's 2022 Clinical Practice Guideline recommends that clinicians prioritize nonpharmacologic and nonopioid pain treatment for specific conditions and patients, considering opioid therapy only when its benefits for pain relief and function outweigh the risks. This shift in pain management strategies highlights the growing role of IV ibuprofen in contemporary healthcare practices.
   
• Moreover, healthcare providers now often combine IV ibuprofen with other analgesics and anesthetics to enhance pain relief while minimizing adverse effects, particularly in postoperative care and pain management protocols. The WHO's pain management guidelines stress the significance of multimodal analgesia in achieving effective pain control. The increasing use of combination therapy involving IV ibuprofen reflects a more advanced approach to pain management in modern medical practice.
   

Intravenous Ibuprofen Market Analysis

Based on product type, the market is bifurcated into conventional IV ibuprofen and high-concentration IV ibuprofen. The conventional IV ibuprofen segment dominated the market with the largest revenue share of 71.3% in 2024.
 

• Conventional IV ibuprofen provides rapid pain relief, making it essential in emergency departments and post-operative care, where immediate pain management is crucial.
   
• Furthermore, growing awareness among healthcare professionals regarding the efficacy and safety of conventional intravenous ibuprofen has led to higher prescription rates across various medical settings. As a result, these factors are expected to significantly drive segment growth throughout the forecast period.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on indication, the IV ibuprofen market is bifurcated into pain management and fever management. The pain management segment dominated the market with the largest revenue of USD 5.7 billion in 2024.
 

• The increasing number of surgical procedures, trauma cases, and chronic pain conditions is driving the demand for effective pain management solutions, thereby increasing the utilization of intravenous ibuprofen. For example, according to the Centers for Disease Control and Prevention (CDC), 24.3% of adults in the U.S. experienced chronic pain in 2023, and 8.5% suffered from high-impact chronic pain. This large patient population creates a demand for reliable and fast-acting pain management options such as IV ibuprofen to improve outcomes and quality of life.
   
• Additionally, hospitals and surgical centers are integrating intravenous (IV) ibuprofen into their pain management protocols because of its effectiveness and reduced side effects compared to opioids.
   
• These factors are anticipated to significantly drive segment growth over the forecast period.
   

Based on age group, the intravenous ibuprofen market is bifurcated into pediatrics and adults. The adults segment dominated the market with the largest revenue of USD 5 billion in 2024.
 

• The growing elderly population, which experiences chronic pain conditions, is driving the demand for effective pain management solutions, including IV ibuprofen. According to the National Institutes of Health, around 20% of older adults globally experience pain, and 10% are newly diagnosed with chronic pain each year. This demographic shift signals sustained demand for IV pain management solutions across healthcare settings.
   
• Additionally, clinical guidelines endorsing IV ibuprofen for adult pain management further strengthen its role in treatment protocols and encourage wider adoption among healthcare providers.
   
• These factors are expected to drive segment growth throughout the forecast period.
   

Based on distribution channel, the intravenous ibuprofen market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment dominated the market with the largest revenue of USD 4.6 billion in 2024.
 

• IV ibuprofen’s ability to provide rapid pain relief makes it highly valuable in acute care settings, increasing demand from healthcare providers and expanding distribution through hospital pharmacies.
   
• Moreover, the focus on patient-centered healthcare approaches is boosting the demand for effective pain management solutions, prompting hospital pharmacies to prioritize IV ibuprofen distribution. These factors are expected to support segment growth throughout the forecast period.
   

The U.S. intravenous ibuprofen market is projected to grow significantly, reaching USD 6.9 billion by 2034.
 

• The increasing prevalence of conditions requiring pain management, such as postoperative pain, musculoskeletal disorders, and injuries, is fueling the demand for intravenous (IV) ibuprofen in the U.S. According to the CDC, 24.3% of U.S. adults experienced chronic pain in 2023, while 8.5% suffered from high-impact chronic pain. This substantial patient population highlights the significant need for effective pain management solutions like IV ibuprofen.
   
• Additionally, the approval of IV ibuprofen for pain management by the U.S. Food and Drug Administration (FDA) supports its widespread use across hospitals and clinical settings. The FDA's safety communication confirms IV ibuprofen’s effectiveness in managing mild to moderate pain, as well as its use as an adjunct to opioid analgesics for moderate to severe pain. This regulatory endorsement strengthens healthcare providers' confidence in prescribing IV ibuprofen as a reliable pain management solution.
   

The IV ibuprofen market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The National Health Service (NHS) has established clinical guidelines recommending IV ibuprofen for pain management, especially in post-operative care and emergency departments. This endorsement has encouraged its adoption across UK hospitals.
   
• Additionally, the UK healthcare system emphasizes reducing opioid prescriptions to mitigate the risks of addiction and adverse effects. According to NHS England, general practitioners (GPs) and pharmacists in England have reduced opioid prescriptions by 450,000 in under four years. IV ibuprofen serves as an effective non-opioid alternative for pain management, aligning with national healthcare goals.
   

Japan intravenous ibuprofen market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan’s aging population has led to higher rates of chronic pain and age-related conditions, increasing the demand for effective pain management solutions such as intravenous (IV) ibuprofen. According to the World Health Organization (WHO), 29.1% of Japan’s population was aged 65 years or older in 2023, the highest proportion globally.
   
• Similarly, the Health and Global Policy Institute reports that 22.5% of Japan’s adult population suffers from chronic pain, affecting approximately 23.15 million people. This demographic trend signals sustained growth in demand for IV pain management solutions in the years to come.
   
• Additionally, clinical guidelines in Japan recommend IV ibuprofen for pain management, particularly in hospital settings, further boosting its adoption in healthcare protocols.
   

The intravenous ibuprofen market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The expansion of outpatient surgical facilities and pain management centers in Saudi Arabia is driving the adoption of intravenous ibuprofen for pain relief.
   
• Additionally, the regulatory framework established by the Saudi Food and Drug Authority (SFDA) supports the use of non-opioid medications, including IV ibuprofen, in medical treatment protocols.
   

Intravenous Ibuprofen Market Share

The market is fragmented, featuring both major global companies and numerous smaller firms. A key strategy for participants is investing in the development of advanced intravenous (IV) ibuprofen formulation techniques, advanced drug delivery systems, combination therapies, and extended-release formulations, to enhance treatment efficiency. Strategic partnerships with research institutions and healthcare providers are crucial for integrating modern technologies and expanding distribution, enabling companies to address the rising demand for non-invasive and cost-effective diagnostic solutions. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.
 

Intravenous Ibuprofen Market Companies

Some of the eminent market participants operating in the intravenous (IV) ibuprofen industry include:

• AFT Pharmaceuticals
• Al Nabeel International
• Alveda Pharmaceuticals
• CSL Limited
• Cumberland Pharmaceuticals
• Fresenius SE & Co. KGaA
• Grifols
• Harbin Gloria Pharmaceuticals
• Hyloris Pharmaceuticals
• Laboratorios Valmorca
• Recordati
• Sandor Medicaids
• Soho Industri Pharmasi
• Teligent
• XGEN Pharmaceuticals

Intravenous Ibuprofen Industry News:

• In January 2020, Cumberland Pharmaceuticals announced the launch of Caldolor (ibuprofen) Injection in a ready-to-use bag. The new formulation was designed for direct administration without the need for dilution, providing pain relief. This launch strengthened the company’s product portfolio and enhanced its presence in the IV ibuprofen market.
   
• In October 2023, Hyloris Pharmaceuticals announced the U.S. FDA approval of Maxigesic IV, an injectable drug designed for post-operative pain management in hospitals or for patients unable to take oral medications. Maxigesic IV, combining paracetamol and ibuprofen, provides effective pain relief and inflammation reduction without the risk of opioid addiction. This approval bolstered Hyloris Pharmaceuticals' presence in the U.S. market and enhanced its portfolio of innovative non-opioid pain management solutions.
   

The intravenous ibuprofen market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Conventional IV ibuprofen
• High-concentration IV ibuprofen

Market, By Indication

• Pain management
• Fever management

Market, By Age Group

• Pediatrics
• Adults

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE